Pre-market hot trades in US stocks: Cyclerion Therapeutics pre-market down 8.33%; Lockheed Martin pre-market up 7.47%

Pre-market Hot Trades in US Stocks Cyclerion is down 8.33% in pre-market trading. Based on recent key news: On January 5, Cyclerion Therapeutics announced a strategic agreement with Medsteer and is advancing the Phase 2 proof-of-concept study for CYC-126. This move aims to treat resistant depression and has led to stock price fluctuations. Source: Reuters On January 3, Medsteer signed an agreement with Cyclerion to jointly develop an anesthesia delivery system and obtained exclusive licensing options. This agreement may impact the company's future R&D direction. Source: SEC announcement On January 6, the company stated that it plans to initiate the Phase 2 study for CYC-126 in the second half of this year, with the progress of equipment integration and drug delivery systems meeting expectations. This news may affect investor confidence. Source: WSJ The biotechnology industry has been volatile recently and requires attention. Lockheed Martin is up 7.47% in pre-market trading. Based on recent key news: On January 8, the U.S. Department of Defense signed an agreement with Lockheed Martin to triple the production capacity of the PAC-3 MSE missile over the next seven years to meet international demand. This move indicates a significant shift in the Pentagon's procurement strategy, driving Lockheed Martin's stock price up. Source: Zhitong Finance On January 8, Trump criticized the shareholder dividends and stock buyback practices of defense contractors on social media, causing Lockheed Martin's stock price to drop 4.82% during regular trading hours. Source: Benzinga On January 8, Lockheed Martin received a $328.5 million contract from the U.S. Department of Defense to provide infrared targets and sensor hardware for Taiwan, further supporting the stock price increase. Source: Benzinga The demand in the defense industry is strong, with increasing policy risks. Top Gainers in Pre-market US Stocks CIMG is up 33.33% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Acrivon Therapeutics is up 26.44% in pre-market trading. Based on recent news, On January 6, Acrivon Therapeutics released an important announcement regarding the company's latest R&D progress and future plans. This news boosted market confidence, leading to a significant rise in stock price. The biotechnology industry has performed strongly recently, with investor sentiment high. ECD Automotive Design is up 25.82% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation